"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet , 402(10404), 529-544
This new medication helps manage blood sugar levels, reduce hunger, and increase fat burning, making it a powerful option for those looking to lose weight effectively and sustainably
572 JainSKParsanathanRAchariAEKanikarla-MariePBocchiniJAJr
Most of this assessment comes in the form of serologic testing that can easily be performed in the physicians office or through a local clinical laboratory
Additionally, heterogeneity among the SNPs was assessed using Cochranes Q test
Advise against its use in patients with a hx of HTN- See phentermine consent for additional details/ medication packet regarding phentermine